Overview

* Voyager Q3 collaboration revenue falls due to lower Novartis agreement revenue

* Net loss widens in Q3 2025 due to increased R&D expenses

* Company maintains cash runway into 2028 with $229 mln cash position

Outlook

* Voyager anticipates VY1706 clinical trial initiation in 2026

* Company expects Neurocrine clinical trial initiations in 2026

* Voyager maintains cash runway guidance into 2028

Result Drivers

* INCREASED R&D EXPENSES - Higher R&D expenses due to MAD clinical trial for VY7523 and tau silencing gene therapy program VY1706

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $13.37

Collabor mln

ation

Revenue

Q3 Net -$27.89

Income mln

Q3 Basic -$0.47

EPS

Q3 -$30.59

Operatin mln

g Income

Q3 -$27.81

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Voyager Therapeutics Inc ( VYGR ) is $12.00, about 64.8% above its November 7 closing price of $4.23

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)